0624 Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy

MLA

Nirogi, Ramakrishna, et al. “0624 Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy.” Sleep, vol. 45, no. 1, Number 1 Supplement 1, June 2022, p. A274. EBSCOhost, https://doi.org/10.1093/sleep/zsac079.621.

APA

Nirogi, R., Ravula, J., Jayarajan, P., Goyal, V. K., Jetta, S., Shinde, A., Benade, V., & Jasti, V. (2022). 0624 Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy. Sleep, 45(1, Number 1 Supplement 1), A274. https://doi.org/10.1093/sleep/zsac079.621

Chicago

Nirogi, Ramakrishna, Jyothsna Ravula, Pradeep Jayarajan, Vinod Kumar Goyal, Satish Jetta, Anil Shinde, Vijay Benade, and Venkat Jasti. 2022. “0624 Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy.” Sleep 45 (1, Number 1 Supplement 1): A274. doi:10.1093/sleep/zsac079.621.